Form 4: Quest Diagnostics SVP Acquires Shares Through Dividend Reinvestment Plan

Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics, acquired 80 shares of common stock through a dividend reinvestment plan.

Summary

• Patrick Plewman, Senior Vice President for Diagnostic Services at Quest Diagnostics Inc. (DGX), acquired 80 shares of the company's common stock.
• The transaction occurred on July 21, 2025, at a price of $167.494 per share.
• The acquisition was made pursuant to a dividend reinvestment plan administered by Mr. Plewman's broker, which was eligible for deferred reporting on Form 5 but was reported early on this Form 4.
• Following this transaction, Mr. Plewman beneficially owns a total of 21,185 shares of Quest Diagnostics common stock.
• The reported amount of beneficially owned shares includes exempt purchases made under the company's stock purchase plan since the date of the last Form 4 filing.

Sentiment

Score: 6

Explanation: The acquisition of shares by a senior executive, even a small amount through a dividend reinvestment plan, generally indicates a positive sentiment towards the company's future prospects, though the impact is minor due to the transaction size.

Positives

• SVP Patrick Plewman increased his direct ownership in Quest Diagnostics, which can be interpreted as a sign of confidence in the company's future.
• The acquisition was made through a dividend reinvestment plan, indicating a long-term investment strategy and commitment to the company.

Negatives

• No specific negative points are identified in this insider transaction filing.

Risks

• No specific risks are detailed in this Form 4 filing, which primarily reports an insider transaction.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it solely reports an insider transaction.

Management Comments

• No direct management comments or quotes are included in this Form 4 filing.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or analysis of market trends.

Comparison to Industry Standards

• Not applicable as this filing reports an individual insider transaction and does not contain performance metrics for industry comparison.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters are mentioned in this filing.

Related Party Transactions

• No unusual related party transactions are disclosed; the acquisition was through a standard dividend reinvestment plan available to participants.

Stakeholder Impact

• Shareholders may view the insider acquisition as a minor positive signal of management confidence in the company's performance and outlook.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

The acquisition of 80 shares by a senior executive, while a positive signal of confidence, is a relatively small transaction and does not significantly alter the fundamental investment thesis for Quest Diagnostics. It is a routine transaction via a dividend reinvestment plan, not a large open-market purchase that would typically warrant a change in recommendation.

Keywords

Quest Diagnostics, DGX, insider transaction, Form 4, stock acquisition, dividend reinvestment plan, Patrick Plewman, common stock